| 國立成功大學 |
2024-10 |
TCOG T3221 study: the registry of genetic alterations of Taiwan biliary tract cancer
|
Chiang;N;Hsu;C;Chen;J;Dai;M;Bai;L;Yen;C;Wang;T;Hsieh;Y;Lin;J;Chiu;T;Cheng;H;Yang;Y;Hsiao;C;Chen;L;Chen;M |
| 國立成功大學 |
2024-09-1 |
Decoupling mechanical and chemical effects on energetics of coherent nanoprecipitates with interfacial segregation
|
Chiu;Yu-ning;Yen;Shao-yu;Yu;Chung-yi;Lin;Shih-kang |
| 國立成功大學 |
2024-09 |
2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease--- Part I
|
Chao;Ting-Hsing;Lin;Tsung-Hsien;Cheng;Cheng-;I;Wu;Yen-Wen;Ueng;Kwo-Chang;Wu;Yih-Jer;Lin;Wei-Wen;Leu;Hsing-Ban;Cheng;Hao-Min;Huang;Chin-Chou;Wu;Chih-Cheng;Lin;Chao-Feng;Chang;Wei-Ting;Pan;Wen-Han;Chen;Pey-Rong;Ting;Ke-Hsin;Su;Chun-Hung;Chu;Chih-Sheng;Chien;Kuo-Liong;Yen;Hsueh-Wei;Wang;Yu-Chen;Su;Ta-Chen;Liu;Pang-Yen;Chang;Hsien-Yuan;Chen;Po-Wei;Jimmy;Jyh-Ming;Juang;Jimmy, Jyh-Ming;Lu;Ya-Wen;Lin;Po-Lin;Wang;Chao-Ping;Ko;Yu-Shien;Chiang;Chern-En;Hou;Charles, Jia-Yin;Wang;Tzung-Dau;Lin;Yen-Hung;Huang;Po-Hsun;Chen;Wen-Jone |
| 國立成功大學 |
2024-09 |
Neurodevelopmental disorders in children born to mothers involved in maternal motor vehicle crashes
|
Chang;Ya-Hui;Chien;Yu-Wen;Chang;Chiung-Hsin;Chen;Ping-Ling;Lu;Tsung-Hsueh;Yen;Cheng-Fang;Chiou;Hung-Yi;Tsai;Kuo-Sheng;Li;Chung-Yi |
| 國立成功大學 |
2024-09 |
Adjunctive Therapy with Chinese Herbal Medicine Lowers Risk of Hearing Loss in Type 2 Diabetes Patients: Results from a Cohort-Based Case-Control Study
|
Huang;Hui-Ju;Livneh;Hanoch;Yen;Chieh-Tsung;Lu;Ming-Chi;Chen;Wei-Jen;Tsai;Tzung-Yi |
| 國立成功大學 |
2024-09 |
Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin
|
Chen;Shih-Yao;Wang;Chung-Teng;Huang;Tang-Hsiu;Tsai;Jeng-Liang;Wang;Hao-Tien;Yen;Yi-Ting;Tseng;Yau-Lin;Wu;Chao-Liang;Chang;Jia-Ming;Shiau;Ai-Li |
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-09 |
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005
|
Seo;S;Calderon;B;Chou;H-H;Hsu;C-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Shapira-Frommer;R;Rha;S, Y.;Zhang;Y;Chen;C;Pena;C, E.;Keenan;T;Chen;Y;Dettman;E;Robinson;A, G. |
| 國立成功大學 |
2024-09 |
Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study
|
Chen;X-P;Yen;C, J.;Huang;P;Lin;C-C;Wang;J;Li;D;Li;Y;Gu;S;Li;G;Du;X;Sun;M;Dai;C;Qian;J;Liu;C;Liu;J;Zhuang;Z;Zhang;F;Kong;G;Cheng;Q;Cheng;A-L |
| 國立成功大學 |
2024-09 |
CVM-005: Phase IIa study of CVM-1118, a novel oral antivasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy
|
Yen;C, J.;Chen;M-H;Chen;Y, Y. Y.;Bai;L-Y;Chen;J-S;Hsieh;C-H, J.;Shih;Y-H;Wu;I-C;Chen;Y-L;Chen;C-M;Chao;T-Y;Chu;Y-W;Chien;D-S |
